title: [Estrogen-progestin contraception and biohumoral response of new markers of the atheroma risk. Behavior of lipoprotein(a) and apolipoproteins A and B].
abstract: A homogeneous group of 45 patients, aged between 19 and 37 years was considered in relationship to metabolic response during oral contraceptive use. A free endocrinological-metabolic pathology control group, formed by 30 patients, aged between 22 and 35, who were not treated with any therapy in the six months before, was also considered. We also considered any other factors like smoking, height, and weight in all women of our study. Study-trial was comprehensive of a 12 months follow-up, with some periods of study at 0, +6, +12 months. Metabolic responses of lipoprotein(a) and apolipoprotein A and B during the different follow-up steps were determined. Total and fractionated cholesterol and triglycerides were also determined. Positive correlations were shown between Lipo(a) and Apo B and also between total cholesterol and LDL. Negative correlations were shown between Lipo(a) vs HDL and Apo A. Lipoprotein(a) was determined by the ELISA technique and turbidimetric technique. The aim of our study was to verify the importance of the new markers of atheroma risk; even if the oral estrogen-progestin contraception little interferes with this biohumoral marker synthesis, it improves atheroma risk protection through the lipidic metabolism complexity.
authors.affiliation: Cattedra di Clinica Ostetrica e Ginecologica, Facoltà di Medicina e Chirurgia-Novara, Università degli Studi, Torino.
authors.forename: A
authors.initials: A
authors.lastname: Porcelli
authors.forename: L
authors.initials: L
authors.lastname: Calleri
authors.forename: D
authors.initials: D
authors.lastname: Gallello
authors.forename: C
authors.initials: C
authors.lastname: Taccani
authors.forename: N
authors.initials: N
authors.lastname: Surico
mesh_terms: D000328:Adult; D001054:Apolipoproteins A / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D001161:Arteriosclerosis / Q000453:epidemiology*; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood*; D009391:Nephelometry and Turbidimetry; D011372:Progestins / Q000494:pharmacology; D012307:Risk Factors; D013997:Time Factors
chemical_list: D001054:Apolipoproteins A; D001055:Apolipoproteins B; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D017270:Lipoprotein(a); D011372:Progestins